Sermorelin and Tesamorelin target the same receptor (GHRH-R) on the same cells (pituitary somatotrophs) to produce the same output (growth hormone). The difference is duration — and that difference has significant research implications.

Sermorelin is rapidly degraded by DPP-IV, producing a brief GH pulse that closely mimics the natural GHRH signal: a short burst followed by return to baseline. This is advantageous for studying physiological pulsatile GH secretion but limits cumulative GH exposure.

Tesamorelin's hexenoic acid modification blocks DPP-IV, extending its active duration from minutes to hours. This produces a longer, more sustained GH release — useful for body composition studies where sustained GH exposure is needed but less physiological than Sermorelin's brief pulse pattern.

Tesamorelin's current FDA approval provides clinical data that Sermorelin's discontinued approval cannot match: - Visceral fat reduction measured by CT scan - Hepatic fat reduction measured by MRI - Body composition changes over 26+ weeks - Safety data in metabolic populations

Sermorelin's clinical heritage is primarily diagnostic (GHRH stimulation testing) rather than therapeutic — it confirms pituitary function rather than producing sustained body composition changes.

For body composition research: Tesamorelin has the clinical evidence edge. For physiological GH release research: Sermorelin better mimics natural GHRH kinetics. For GHRH receptor pharmacology: Both work — they hit the same receptor. For combination with Ipamorelin: Either works, but Sermorelin's shorter pulse may better complement Ipamorelin's brief GH amplification.